OakChart

Sol-Gel Technologies Ltd

SLGLHealthcare·Biotechnology·Israel·Micro·NASD·Nov 11 • 11:14 AM ET

63.85+2.35 (3.83%)
2026-11-11 17:26 CET
Market cap
201.35 USD m
Revenue, TTM
1.79 USD m
Net income, TTM
-16.34 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-5.64
P/E
-
Compare

Price

SLGL against its 20, 50 and 200-day averages
2050200beatearnings
50.0060.0070.0080.0090.0074K148KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SLGLclose 63.8620-day 65.8050-day 67.24200-day 74.0463.86

34.8% under the 52-week high of 97.97 on 3 Mar 2026. 52-week low 28.81 on 13 Nov 2025. Last 15 sessions, 20.0% high to low

Profile

SLGL
52-week range, 51% of the way up
28.8197.97

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Employees28
IPOFeb 01, 2018
Beta1.25
ATR, 14d3.82
Rel volume0.25
Short float10.23%
Insider own59.73%
Inst own45.17%

Snapshot

6 groups

Valuation

Index-
Market Cap209.06M
Enterprise Value161.90M
Income-16.34M
Sales1.79M
Book/sh14.69
Cash/sh14.64
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees28
IPOFeb 01, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S116.79
P/B4.35
P/C4.36
P/FCF-
EV/EBITDA-
EV/Sales90.45
Quick Ratio10.37
Current Ratio10.37
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortNo / Yes

Earnings

EPS (ttm)-5.64
EPS next Y-9.06
EPS next Q-2.07
EPS this Y-253.14%
EPS next Y-16.88%
EPS next 5Y-
EPS past 3/5Y30.15% 29.88%
Sales past 3/5Y70.92% 17.19%
EPS Y/Y TTM-361.11%
Sales Y/Y TTM-92.50%
EPS Q/Q-127.01%
Sales Q/Q-96.58%
EarningsAug 20 BMO
EPS/Sales Surpr.52.12% 688.00%

Ownership

Insider Own59.73%
Insider Trans3.44%
Inst Own45.17%
Inst Trans2.52%
ROA-35.11%
ROE-40.85%
ROIC-33.79%
Gross Margin-
Oper. Margin-989.97%
Profit Margin-910.14%
SMA20-2.95%
SMA50-5.04%
SMA200-13.75%
Trades-

Technical

Shs Outstand3.27M
Shs Float1.32M
Short Float10.23%
Short Ratio2.74
Short Interest0.14M
52W High97.97 -34.82%
52W Low28.81 121.64%
Volatility5.92% 6.06%
ATR (14)3.82
RSI (14)44.28
Beta1.25
Rel Volume0.25
Avg Volume49.37K
Volume4,136

Performance

Perf Week-3.25%
Perf Month-6.51%
Perf Quarter-24.02%
Perf Half Y-12.59%
Perf YTD51.53%
Perf Year100.29%
Perf 3Y362.72%
Perf 5Y-29.68%
Perf 10Y-
Recom1.00
Target Price152.50
Prev Close61.50
Price63.85
Change %3.83%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Oct 14, 2026InitiatedCCantor FitzgeraldOverweight
Jun 24, 2026InitiatedMMizuhoOutperform$285+346.3%
May 29, 2026InitiatedTTD CowenBuy
Aug 19, 2024DowngradeRRaymond JamesStrong Buy → Outperform$6 → $4-93.7%
Oct 21, 2022ResumedJJefferiesHold$5.50-91.4%
Dec 31, 2019ReiteratedJJMP SecuritiesMkt Outperform$20 → $33-48.3%
Dec 31, 2019ReiteratedHH.C. WainwrightBuy$23 → $26-59.3%

Peers

Mkt cap
TickerCompanyMkt cap
PVLAPalvella Therapeutics Inc2.46B
VRCAVerrica Pharmaceuticals Inc63.39M
PTHSPelthos Therapeutics Inc36.52M
ARQTArcutis Biotherapeutics Inc3.55B
ACRSAclaris Therapeutics Inc693.13M
DERMJourney Medical Corp125.74M
EVMNEvommune Inc320.82M
BFRIBiofrontera Inc13.92M
KRYSKrystal Biotech Inc9.10B
DRMADermata Therapeutics Inc3.48M

Insider trading

latest 14 of 46
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Opaleye Management Inc.10% OwnerSep 10 '26Buy66.801,631108,943538,507Sep 14 05:23 PM
Opaleye Management Inc.10% OwnerSep 11 '26Buy65.941,49398,456540,000Sep 14 05:23 PM
Opaleye Management Inc.10% OwnerSep 08 '26Buy68.823,861265,703533,779Sep 09 07:18 PM
Opaleye Management Inc.10% OwnerSep 09 '26Buy68.703,097212,779536,876Sep 09 07:18 PM
Opaleye Management Inc.10% OwnerSep 04 '26Buy69.143,018208,677529,918Sep 09 07:18 PM
Opaleye Management Inc.10% OwnerSep 02 '26Buy68.9590062,054526,900Sep 03 04:05 PM
Opaleye Management Inc.10% OwnerSep 01 '26Buy69.5278354,434526,000Sep 03 04:05 PM
Opaleye Management Inc.10% OwnerAug 28 '26Buy69.3235,1132,434,156520,000Aug 31 06:24 PM
Opaleye Management Inc.10% OwnerAug 31 '26Buy68.275,217356,170525,217Aug 31 06:24 PM
Opaleye Management Inc.10% OwnerAug 12 '26Buy71.5095167,996494,887Aug 14 04:05 PM
Opaleye Management Inc.10% OwnerJul 14 '26Buy73.4392067,556493,936Jul 15 04:05 PM
Opaleye Management Inc.10% OwnerJul 13 '26Buy73.8977557,263493,016Jul 15 04:05 PM
Opaleye Management Inc.10% OwnerJul 08 '26Buy73.6930022,107492,012Jul 10 04:41 PM
Opaleye Management Inc.10% OwnerJul 10 '26Buy73.9522916,935492,241Jul 10 04:41 PM

Held by

AUM
TickerCompanyAUM
IZRLARK Israel Innovative Technology ETFAUM: 118.95M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 206
  • Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 (GlobeNewswire)
  • Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome (GlobeNewswire)
  • Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire) -6.06%
  • Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Loading…
  • Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering (GlobeNewswire) -9.28% +20.86%
  • Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025 (GlobeNewswire) +8.46%
  • This Under-the-Radar Stock Has Surged 1,300% Over the Past Year (Barchart) -9.52%
  • Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease (GlobeNewswire)
  • Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Sol-Gel Announces Health Canada Approval of EPSOLAY (GlobeNewswire) +19.66%
  • Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Sol-Gel Reports First Quarter 2025 Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-20-1.130-2.360-1.1260.590.083
2026Q12026-05-28-1.310-2.860-1.3140.110.901
2025Q42026-03-11-1.5800.390-1.0726.506.501
2025Q32025-11-20-2.130-2.090-2.1330.400.301
2025Q22025-08-154.170-4.16817.26--
2025Q12025-05-23-3.200--3.1621.00--
2024Q32024-11-15-0.100-0.500-0.1315.364.201
2024Q22024-08-160.700-2.0000.7095.431.052
2024Q12024-05-20-2.300-1.550-2.2770.470.932
2023Q42024-03-13-1.700-1.750-1.736-0.050.252
2023Q32023-11-09-2.100-2.300-2.0510.210.692
2023Q22023-08-10-2.200-2.550-2.1580.591.552
2023Q12023-05-12-4.100-2.150-4.1140.800.482
2022Q42023-03-10-2.500-1.250-2.5010.101.842
2022Q32022-11-10-1.500-0.713-1.4730.263.423
2022Q22022-08-04-0.100-0.967-0.0583.524.613

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-12.600-13.020-12.59822.9023.14
2020FY-13.000-14.825-12.9758.778.30
2021FY1.400-0.5501.36731.4728.50
2022FY-6.500-5.200-6.4523.895.68
2023FY-10.100-10.100-10.0561.551.15
2024FY--2.800-3.798-13.30
2025FY-2.195-0.740-10.10019.2025.20
2026FY--7.752--1.02
2027FY--9.060--0.85
2028FY--10.900--9.61
2029FY--8.700--35.16
2030FY-0.565--84.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-132100.150.000.30
2026Q3S2026-10-051100.300.300.30
2026Q3S2026-09-141000.200.200.20
2026Q3S2026-08-202000.100.000.20
2026Q3S2026-08-112000.100.000.20
2026Q3S2026-07-172010.100.000.20
2026Q3S2026-06-231000.000.000.00
2026Q3S2026-03-111001.501.501.50
2026Q3S2025-11-201001.501.501.50
2026Q3S2025-11-111001.501.501.50
2026Q3S2025-11-101001.501.501.50
2026Q3S2025-11-091001.501.501.50
2026Q3S2025-11-081001.501.501.50
2026Q3S2025-11-071001.501.501.50

Estimate history

EPS, annual-50.2-18.023-12.598-12.9751.367-6.452-10.056-3.798-2.199-5.6444
Period201720182019202020212022202320242025TTM
EPS, quarterly0.709-0.131-2.099-3.1624.168-2.133-1.072-1.314-1.126
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.1740.12922.9048.77131.2723.8831.55411.53819.3881.79
Period201720182019202020212022202320242025TTM
Sales, quarterly5.4335.3610.2781.03117.2610.40.6960.1080.591
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6291.8952.042.32.3132.3132.7862.7862.7863.274
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.7862.7862.7862.7862.7862.7862.7863.2693.274
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.7919.3911.541.553.8831.278.7722.900.13
Cost of Goods Sold Incl. D&A-0.110.230.34-----
Gross Profit-19.2811.301.21-----
Selling, General and Administrative Excl. Other19.5726.8723.3230.5719.5727.9538.0647.9732.89
Research and Development15.8222.7017.8023.5412.6820.3827.9140.5828.15
Other Operating Expense0.000.000.000.000.00-0.000.000.00
Operating Income-17.77-7.59-12.01-29.36-16.242.44-30.23-25.95-33.52
Interest Expense--------0.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-16.34-6.13-10.58-27.24-14.923.22-29.29-24.58-32.20
Income Taxes0.000.000.000.000.000.000.000.030.00
Consolidated Net Income-16.34-6.13-10.58-27.24-14.923.22-29.29-24.61-32.20
Net Income From Continuing Operations-16.34-6.13-10.58-27.24-14.923.22-29.29-24.61-32.20
Net Income-16.34-6.13-10.58-27.24-14.923.22-29.29-24.61-32.20
EPS (Recurring)-5.00-2.20-3.80-10.06-6.451.37-12.97-12.60-18.02
EPS (Basic, Before Extraordinaries)-5.64-2.20-3.80-10.06-6.451.40-12.97-12.60-18.02
EPS (Diluted)-5.64-2.20-3.80-10.06-6.451.37-12.97-12.60-18.02
EBITDA--7.48-11.78-29.02-15.683.32-29.29-25.06-32.76
Non-Operating Income (Expense)1.431.471.432.121.320.780.941.371.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.080.791.861.530.691.222.554.65
Price To Earnings Ratio----21.5554.05---
Price To Sales Ratio135.096.062.2519.2627.165.5825.2014.63833.82
Gross Margin-99.4497.9877.99-----
Operating Margin-989.97-39.16-104.13-1,889.32-418.347.80-344.69-113.30-25,985.27
Net Margin-910.14-31.60-91.70-1,752.77-384.3210.30-333.94-107.44-24,963.57
Shares Outstanding3.272.792.792.792.312.312.302.041.89
Market Capitalization201.35201.3525.9130.78105.47171.14225.18349.91114.08

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.590.110.700.4017.261.030.285.36
Selling, General and Administrative Excl. Other4.753.964.166.696.0310.106.386.19
Research and Development3.722.793.585.734.658.845.204.82
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.16-3.85-3.46-6.2911.23-9.07-6.10-0.83
Interest Expense0.00-------
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.68-3.73-2.99-5.9411.61-8.81-5.85-0.37
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.68-3.73-2.99-5.9411.61-8.81-5.85-0.37
Net Income From Continuing Operations-3.68-3.73-2.99-5.9411.61-8.81-5.85-0.37
Net Income-3.68-3.73-2.99-5.9411.61-8.81-5.85-0.37
EPS (Recurring)-1.13-1.31-1.07-2.134.17-3.16-2.10-0.13
EPS (Basic, Before Extraordinaries)-1.13-1.31-1.07-2.134.17-3.16-2.10-0.13
EPS (Diluted)-1.13-1.31-1.07-2.134.17-3.16-2.10-0.13
Non-Operating Income (Expense)0.480.130.480.350.380.260.250.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.15---0.10---
Price To Sales Ratio135.0912.176.064.280.861.202.251.62
Operating Margin-704.23-3,569.44-497.84-1,572.0065.06-879.63-2,193.88-15.44
Net Margin-622.84-3,450.93-429.17-1,485.5067.26-854.32-2,102.88-6.83
Shares Outstanding3.273.272.792.792.792.792.792.79
Market Capitalization201.35258.97117.3981.2020.6114.4925.9118.94

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments24.0023.9338.0033.6343.2450.1750.3862.999.02
Short Term Receivables1.973.600.387.8613.062.154.120.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.003.772.791.570.801.071.292.991.52
Total Current Assets26.9731.3041.1743.0557.1153.4055.7965.9710.55
Net Property, Plant & Equipment1.171.632.151.542.553.714.352.602.31
Total Investments and Advances1.321.291.281.291.301.290.470.000.12
Long-Term Note Receivable0.001.02-0.007.40--0.001.65
Intangible Assets---0.000.000.000.000.000.00
Other Assets0.460.610.680.750.830.750.681.100.68
Total Assets29.9235.8545.2946.6369.1959.1661.3069.6815.31
Short Term Debt Incl. Current Port. of LT Debt0.490.430.450.720.780.670.670.000.00
Accounts Payable0.731.260.150.250.771.201.712.920.53
Other Current Liabilities4.943.593.922.3610.144.094.121.9766.67
Total Current Liabilities6.175.294.523.3311.695.966.504.8967.20
Long Term Debt0.500.881.210.050.811.301.370.000.00
Provision for Risks Charges0.440.830.921.031.091.050.960.880.81
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities7.117.006.644.4213.608.318.845.7768.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity22.8128.8538.6442.2155.5950.8552.4763.91-52.70
Total Shareholders Equity22.8128.8538.6442.2155.5950.8552.4763.91-52.70
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity22.8128.8538.6442.2155.5950.8552.4763.91-52.70
Total Liabilities & Stockholders Equity29.9235.8545.2946.6369.1959.1661.3069.6815.31
Book Value Per Share8.1910.3613.8718.2524.0422.1125.7133.73-83.78
Tangible Book Value Per Share8.1910.3613.8718.2524.0422.1125.7133.73-83.78
Full-Time Employees2834365553656156-
Price to Book Ratio4.190.900.712.223.084.436.671.521.52
Return on Assets-18.63-26.08-59.27-25.775.02-48.63-37.58-75.77-240.06
Return on Equity-23.72-31.35-67.37-30.526.05-56.70-42.29-574.54-
Return on Invested Capital-26.29-35.59-68.35-35.315.71-56.17-45.71-50.39-
Quick Ratio4.375.929.1012.934.888.958.5813.480.16
Current Ratio4.375.929.1012.934.888.958.5813.480.16

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--6.13-10.58-27.24-14.923.22-29.29-24.61-32.20
Depreciation-0.110.230.340.560.880.950.890.76
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00
Other Funds (Non Cash)-0.150.861.501.340.631.462.714.76
Funds from Operations--5.87-9.49-25.40-13.024.73-26.89-21.01-26.69
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-6.19-4.407.673.54-12.421.64-1.493.22
Cash from Operating Activities-0.32-13.89-17.73-9.48-7.69-25.24-22.50-23.47
Capital Expenditures--0.05-0.00-0.13-0.17-0.14-0.45-0.60-1.05
Net Assets From Acquisitions-0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.050.010.070.000.000.000.00-
Purchase or Sale of Investments--8.5715.87-11.361.8720.02-2.2516.62-53.69
Purchase of Investments--14.080.00-23.16-10.01-6.77-53.74-38.71-71.78
Sale Or Maturity of Investments-5.5115.8711.8111.8826.7851.5055.3318.09
Other Uses--0.030.00-0.810.000.000.000.000.00
Other Sources-0.0110.822.490.000.000.000.000.01
Cash from Investing Activities--8.5826.69-9.741.7019.87-2.6916.02-54.74
Cash Dividends Paid-0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Change in Capital Stock-0.010.0021.810.020.8426.4610.6178.82
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-0.010.0021.810.020.8426.4610.6178.82
Proceedsfrom Stock Options-0.000.0021.540.000.5126.3110.6178.78
Issuance or Reduction of Debt, Net-0.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.000.00
Cash from Financing Activities-0.010.0021.810.020.8426.4610.6178.82
Exchange Rate Effect--0.19-0.00-0.070.13-0.06-0.01-0.050.03
Net Change in Cash--8.4412.80-5.74-7.6412.96-1.494.090.65
Free Cash Flow-0.28-13.89-17.86-9.65-7.83-25.69-23.10-24.52
Price to Free Cash Flow-426.90-------

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments47.9352.8324.0020.8424.2916.90
Short Term Receivables0.711.071.979.8510.043.88
Inventories0.000.000.000.000.000.00
Other Current Assets2.441.891.000.961.942.65
Total Current Assets51.0855.7926.9731.6536.2623.43
Net Property, Plant & Equipment0.921.041.171.281.391.51
Total Investments and Advances1.341.331.321.311.311.29
Intangible Assets0.000.00-0.000.000.00
Other Assets0.420.400.460.350.340.30
Total Assets53.7658.5529.9234.5939.3127.06
Short Term Debt Incl. Current Port. of LT Debt0.520.480.490.490.480.43
Accounts Payable4.410.780.730.831.170.44
Other Current Liabilities-0.005.054.944.833.313.70
Total Current Liabilities4.936.316.176.154.964.57
Long Term Debt0.250.380.500.590.700.75
Provision for Risks Charges0.480.450.440.420.410.36
Other Liabilities0.000.000.001.401.351.21
Total Liabilities5.667.147.118.567.426.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity48.1051.4122.8126.0331.8820.17
Total Shareholders Equity48.1051.4122.8126.0331.8820.17
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity48.1051.4122.8126.0331.8820.17
Total Liabilities & Stockholders Equity53.7658.5529.9234.5939.3127.06
Book Value Per Share14.6915.738.199.3411.447.24
Tangible Book Value Per Share14.6915.738.199.3411.447.24
Full-Time Employees--28---
Price to Book Ratio4.199.684.512.551.020.72
Return on Assets-35.11-2.44-18.63-23.17-8.39-38.95
Return on Equity-40.85-2.92-23.72-29.59-10.21-49.39
Return on Invested Capital-7.61-7.20-12.82-22.3235.63-42.11
Quick Ratio10.378.844.375.157.325.12
Current Ratio10.378.844.375.157.325.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1

Revenue breakdown

License2024: 9.80M 2025: 18.60M
Royalty2024: 1.62M 2025: 707.00K
Service, Other2024: 126.00K 2025: 82.00K
Canada2024: 681.00K 2025: 1.68M
China2024: 4.87M 2025: 27.00K
Israel2024: 3.81M
Segment Geographical Groups Of Countries Group Five2024: 691.00K 2025: 278.00K
Switzerland2024: 1.48M 2025: 711.00K
United States2025: 16.70M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.23%0.1M1.3M53.60K
2026-10-1510.32%0.1M1.3M55.26K
2026-09-3011.05%0.1M1.3M54.59K
2026-09-159.26%0.1M1.3M51.26K
2026-08-315.61%0.1M1.3M47.67K
2026-08-143.79%0.0M1.3M43.46K
2026-07-314.09%0.1M1.3M35.39K
2026-07-153.56%0.0M1.3M31.14K
2026-06-303.63%0.0M1.3M40.44K
2026-06-154.00%0.1M1.3M42.39K
2026-05-294.05%0.1M1.3M41.42K
2026-05-151.91%0.0M1.3M38.71K
2026-04-303.03%0.0M1.3M40.88K
2026-04-151.43%0.0M1.3M40.38K
2026-03-311.28%0.0M1.0M29.45K
2026-03-132.19%0.0M0.8M25.83K
2026-02-271.07%0.0M0.8M23.42K
2026-02-130.69%0.0M0.8M21.35K
2026-01-300.90%0.0M0.8M20.86K
2026-01-151.13%0.0M0.8M18.34K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13GSEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-13SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-09SCHEDULE 13G/ASEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-15SCHEDULE 13D/ASEC
2026-03-31SCHEDULE 13GSEC
2026-03-244Statement of changes in beneficial ownership of securities2026-03-24SEC
2026-03-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-24SEC
2026-03-24424B5SEC
2026-03-23EFFECTEffectiveness filing by commission orderSEC
2026-03-23SCHEDULE 13G/ASEC
2026-03-19POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-03-1920-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-091.01M700
2026-082.86M300
2026-07287.08K600
2026-060000
2026-05332.21K300
2026-040000
2026-032.86M100
2026-0224.13K200
2026-01301.92K500
2025-123.30M1200
2025-11245.18K300

Institutional holders

Manager% owned
Opaleye Management Inc.15.30%
GREAT POINT PARTNERS LLC8.39%
Trails Edge Capital Partners, LP4.27%
Phoenix Financial Ltd.3.47%
Affinity Asset Advisors, LLC2.60%
Squadron Capital Management LLC1.59%
CITADEL ADVISORS LLC1.00%
GILDER GAGNON HOWE & CO LLC0.69%
Stonepine Capital Management, LLC0.44%
Yelin Lapidot Holdings Management Ltd.0.28%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND76.26%
VANGUARD DEVELOPED MARKETS INDEX FUND50.32%
iShares Core MSCI EAFE ETF39.40%
Fidelity International Index Fund20.41%
iShares MSCI EAFE ETF18.34%
VANGUARD FTSE ALL-WORLD EX-US INDEX FUND12.41%
Schwab International Equity ETF11.97%
iShares MSCI Israel ETF11.33%
Fidelity Series Global ex U.S. Index Fund10.40%
iShares MSCI EAFE Growth ETF7.99%

OakChart. SLGL. Cached 15 minutes.